The Biotechnology Industry Association (BIA), the representative body of international biotech product makers, has expressed concern over the patent criteria norms prescribed under the Indian Patent Act. In a representation to the office of the US Trade Representative (USTR) on February 11, the association has demanded that India be kept under the priority watch list of USTR due to inadequate intellectual property (IP) compliance.